Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 16/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | NQO2 | P16083 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14005910 | 0.91 | MTNR1A (0.49) | MTNR1AL3MBTL1TDP1KDM4EALDH1A1 | |
| SCHEMBL9482196 | 0.89 | L3MBTL1 (0.58) | MTNR1AL3MBTL1TDP1KDM4EALDH1A1 | |
| SCHEMBL15509773 | 0.87 | MTNR1A (0.64) | MTNR1AL3MBTL1TDP1MTNR1BHTR2C | |
| SCHEMBL15747753 | 0.86 | MTNR1A (0.60) | MTNR1AMTNR1B | |
| SCHEMBL15307895 | 0.85 | MTNR1A (0.64) | MTNR1AL3MBTL1TDP1MTNR1BHTR2C | |
| SCHEMBL15305557 | 0.85 | L3MBTL1 (0.50) | L3MBTL1TDP1KDM4EALDH1A1GLA | |
| SCHEMBL15747703 | 0.84 | MTNR1A (0.61) | MTNR1AMTNR1B | |
| SCHEMBL15747695 | 0.83 | KDM4E (0.55) | MTNR1AL3MBTL1TDP1KDM4EALDH1A1 | |
| SCHEMBL3914252 | 0.83 | MTNR1A (0.64) | MTNR1ATDP1MTNR1BHTR2CHTR2B | |
| SCHEMBL30692247 | 0.83 | MTNR1A (0.64) | MTNR1ATDP1MTNR1BHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2703383-A1 | Process for the preparation of agomelatine | Procos S.p.A. (IT) | 2014-03-05 | — | — | EP | claimed |
| WO-2012070025-A1 | PROCESS FOR THE PREPARATION OF AGOMELATINE | CADILA PHARMACEUTICALS LTD (IN) | 2012-05-31 | — | — | WO | claimed |
| CN-117776934-A | Preparation method of agomelatine intermediate | 江苏威奇达药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117720424-A | Continuous flow preparation method of agomelatine intermediate | 江苏威奇达药业有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-113527139-A | Method for synthesizing 7-methoxy-1-naphthylacetonitrile and intermediate | 上海法默生物科技有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-107353229-B | A kind of preparation method of agomelatine intermediate body | 许昌恒生制药有限公司 | 2019-04-30 | — | — | CN | disclosed |
| CN-108373422-A | A kind of preparation method of agomelatine | 无锡富泽药业有限公司 | 2018-08-07 | — | — | CN | disclosed |
| CN-107353229-A | A kind of preparation method of agomelatine intermediate body | 许昌恒生制药有限公司 | 2017-11-17 | — | — | CN | disclosed |
| CN-104230754-B | A kind of synthetic method of (7-methoxy-1-naphthyl) acetonitrile | ZHEJIANG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2017-01-04 | — | — | CN | disclosed |
| WO-2016046833-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-03-31 | — | — | WO | disclosed |
| CN-102993040-B | A kind of novel method of synthesizing Agomelatine | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2015-09-30 | — | — | CN | disclosed |
| US-20080280991-A1 | SUBSTITUTED NAPHTHALENES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280991-A1 | SUBSTITUTED NAPHTHALENES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2007146136-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| CN-1048720-C | New o-arylmethyl-N-(thio)acylhydroxylamines, process for preparing them and pharmaceutical compositions containing them | ADIR (FR) | 2000-01-26 | — | — | CN | disclosed |
| CN-1127247-A | New o-arylmethyl-N-(thio)acylhydroxylamines, process for preparing them and pharmaceutical compositions containing them | ADIR (FR) | 1996-07-24 | — | — | CN | disclosed |
| US-5449690-A | Antihypercholesterol anf melatonin antagonist | ADIR ET COMPAGNIE (FR) | 1995-09-12 | — | — | US | disclosed |
| US-5449689-A | Treating melatoninergic system disorders | ADIR ET COMPAGNIE (FR) | 1995-09-12 | — | — | US | disclosed |
| US-5389683-A | Useful in treating or preventing a disorder of the melatoninergic system | ADIR ET COMPAGNIE (FR) | 1995-02-14 | — | — | US | disclosed |
| US-5385944-A | Naphthylethylureas and naphthylethylthioureas | ADIR ET COMPAGNIE (FR) | 1995-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280991-A1 | SUBSTITUTED NAPHTHALENES | MTNR1A, MTNR1B, TPH1 | MTNR1A 1/4885L3MBTL1 4882/4885TDP1 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.